Search Browse Earnings

Transcode Therapeutics, Inc. — SlamSEC

Transcode Therapeutics, Inc.

Nasdaq:RNAZ

Pharmaceutical Preparations·BOSTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$19.3M

FY 2024

Net Income

-$18.5M

FY 2024

EPS (Diluted)

-$3419.01

FY 2024

Stock Price

$9.90

+1.3%

2026-03-10

52W Range

$6.08 – $46.76

P/E Ratio

-0.0x

Market Cap

$9.1M

Cash

$2.8M

FY 2024

Total Debt

—

Net Cash

$2.8M

Enterprise Value

$6.3M

Debt / EBITDA

0.1x

FY 2024

EV / EBITDA

-0.3x

Employees

—

CEO

Fitzgerald Thomas A

CFO

Fitzgerald Thomas A